Bristol Myers Squibb to buy Karuna Therapeutics for $14bn

Biopharmaceuticals giant Bristol Myers Squibb has announced it is spending $14bn to purchase Karuna Therapeutics, which develops treatments for people living with psychiatric and neurological conditions.

Related Keywords

Christopher Boerner , Dow Jones , Mizuho Securities , Cereval Therapeutics , Bristol , Myers , Squibb , Karuna , Therapeutics , R4bn , Category All , Category Company News , Categorym A , Category International Companies , Category Sectorial Health Technology , Mostread Company News ,